# Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

> **NCT00392392** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 29 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00392392
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-04
- **Final completion:** 2011-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-09-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392392, "Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00392392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*